Showing results (11-20 of 35) with videos related to
Sort By:
Pageof 4
Cancer Informatics|November 28, 2022
A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 ImmunotherapyEmma Bigelow, Suchi Saria, Brian Piening, et al.Frontiers in Oncology|February 27, 2023
A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanomaAnn W Silk, Brendan Curti, Jennifer Bryan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2021
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable MelanomaRobert H I Andtbacka, Brendan Curti, Gregory A Daniels, et al.Melanoma Research|November 28, 2017
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanomaJason Chesney, Sanjay Awasthi, Brendan Curti, et al.Frontiers in Oncology|January 31, 2020
High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced MelanomaAnn W Silk, Howard L Kaufman, Brendan Curti, et al.Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|February 5, 2021
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2Joseph I Clark, Brendan Curti, Elizabeth J Davis, et al.Journal for Immunotherapy of Cancer|December 20, 2017
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registryBrendan Curti, Gregory A Daniels, David F McDermott, et al.Journal for Immunotherapy of Cancer|July 29, 2018
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanomaJoseph I Clark, Jatinder Singh, Marc S Ernstoff, et al.Journal for Immunotherapy of Cancer|May 16, 2014
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 studyShailender Bhatia, Brendan Curti, Marc S Ernstoff, et al.JCI Insight|September 22, 2023
Regulation of human and mouse bystander T cell activation responses by PD-1Catherine T Le, Logan V Vick, Craig Collins, et al.Pageof 4